The MPP invites Expression of Interest from potential sublicensees for licences to manufacture and sell bictegravir, tenovofir alafenamide, tenofovir disoproxil fumarate, dolutegravir, lopinavir, ritonavir and daclatasvir.
EXPANSION OF THE PATENT AND LICENSING DATABASE, MEDSPAL, TO INCLUDE ESSENTIAL MEDICINES FOR CANCER
MedsPaL, a comprehensive resource for information on the intellectual property status of priority medicines in developing countries, has been expanded to patented treatments on the World Health Organization’s Model List of Essential Medicines.
The MPP’s patents and licences database, MedsPaL is an information resource that provides information on the intellectual property status of selected HIV, hepatitis C, tuberculosis and other patented essential medicines in low- and middle-income countries.
The Medicines Patent Pool (MPP) is currently inviting interested product developers to indicate an interest in a sublicence for investigational hepatitis C (HCV) treatment ravidasvir. Pharco Pharmaceuticals granted the MPP a non-exclusive, royalty-bearing licence which allows sublicensees to develop, make, have made, use, file for regulatory approval, sell, import and export ravidasvir. The full text of the agreement can be found here.
Per the licence’s terms and conditions, the MPP seeks to grant sublicences to any entity that can demonstrate a willingness and capacity to further develop and commercialise the product and make the product widely available in the Territory. The MPP will also require any sublicensee to agree upon reasonable diligence requirements and development milestones.
Interested parties should also submit as much detail as possible to help MPP understand whether, and to what extent, a granted sublicence will help improve sustainable access to improved regimens to treat HCV. Applicat...
Geneva, 14 December 2017 — The Medicines Patent Pool (MPP) Governance Board announced today that Greg Perry, Executive Director of the foundation since January 2013, has resigned from his post to pursue new opportunities.
In nearly five years with the MPP, Perry has succeeded in establishing the MPP as the leading patent pooling and voluntary licensing mechanism dedicated to ensuring affordable access to medicines for people living in low- and middle-income countries.
“Greg leaves the MPP in a very strong position for its future work in improving treatment options in developing countries. The Board would like to thank him for his invaluable contribution and leadership during his time as Executive Director,” said Marie-Paule Kieny, Chair of the foundation’s Governance Board. “We wish him every success in his next projects.”
During Greg Perry’s tenure, the MPP has gained the confidence of originator and generic pharmaceutical companies, civil society groups, governments and international organisations....
Geneva, 12 December 2017 — The Medicines Patent Pool (MPP) has signed collaborative agreements with additional patent offices, Argentina’s National Institute of Industrial Property (INPI) and Brazil’s National Institute of Industrial Property (INPI) to augment data on MedsPaL, its signature resource for patent and licensing information in developing countries. Argentina’s and Brazil’s national patent offices are contributing crucial data on the intellectual property status of medicines on the World Health Organization’s Model List of Essential Medicines (WHO EML) to guide public health actors in making procurement and supply decisions.
To date, the MPP has signed eight agreements with national and regional offices, including with the European Patent Office, which provides automatic data feeds from the European Patent Office’s public database Espacenet. Memoranda of Understanding with the patent offices of Chile, Dominican Republic, Ecuador, El Salvador and South Africa help keep MedsPaL information current...
“Successful cooperation of the Ministry of Health of Belarus with the Medicines Patent Pool is crucial in light of our current work to achieve the “90-90-90” goals and put an end to the epidemic in the country which is only possible when access to affordabl...”